Rigosertib (ON-01910)

目录号:S1362

仅限科研使用

Rigosertib (ON-01910) 是一种非ATP竞争性PLK1抑制剂,无细胞试验中IC50为9 nM,比作用于Plk2选择性高30倍,对Plk3没有抑制活性。Rigosertib 可抑制 PI3K/Akt 信号通路并激活氧化应激信号。Rigosertib 可诱导多种癌细胞的凋亡。Phase 3。

Rigosertib (ON-01910) Chemical Structure

CAS: 1225497-78-8

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 2630.22 现货
RMB 1381.36 现货
RMB 7944.48 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Rigosertib (ON-01910)发表文献31篇:

产品安全说明书

PLK抑制剂选择性比较

相关PLK产品

生物活性

产品描述 Rigosertib (ON-01910) 是一种非ATP竞争性PLK1抑制剂,无细胞试验中IC50为9 nM,比作用于Plk2选择性高30倍,对Plk3没有抑制活性。Rigosertib 可抑制 PI3K/Akt 信号通路并激活氧化应激信号。Rigosertib 可诱导多种癌细胞的凋亡。Phase 3。
特性 Rigosertib是作用于Polo样激酶(PLK1)的非ATP竞争性抑制剂。
靶点
PLK1 [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
Bcr-Abl [1]
(Cell-free assay)
Flt1 [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
点击更多
9 nM 18 nM 32 nM 42 nM 155 nM
体外研究

Rigosertib是PLK1的非ATP竞争性抑制剂,IC50为9 nM。Rigosertib也抑制 PLK2,PDGFR,Flt1,BCR-ABL,Fyn,Src和CDK1, IC50为18-260 nM。Rigosertib具有使细胞死亡的活性,作用于94种不同肿瘤细胞系,IC50为50-250 nM,包括BT27,MCF-7,DU145,PC3,U87,A549,H187,RF1,HCT15,SW480,和KB细胞。Rigosertib作用于正常细胞,如 HFL,PrEC,HMEC,和HUVEC没有效果,除非作用浓度高于5-10 µM。100-250 nM Rigosertib作用于HeLa 细胞,诱导纺锤体变异和凋亡。[1] Rigosertib也抑制一些多重耐药的的肿瘤细胞系,包括 MES-SA, MES-SA/DX5a, CEM, 和 CEM/C2a, IC50为50-100 nM。0.25-5 µM Rigosertib作用于DU145细胞, 抑制细胞周期,使细胞停在G2/M 期,和激活凋亡通路。50 nM-0.5 µM Rigosertib作用于A549细胞,诱导存活力和caspase 3/7激活的丧失。[2]最新研究显示, Rigosertib作用于慢性淋巴细胞性白血病 (CLL)细胞,诱导凋亡,且作用于T细胞或正常B细胞没有毒性。Rigosertib 慢性淋巴细胞性白血病(CLL)细胞,也抑制滤泡树突状细胞的促生存效果,作用于白血病细胞,降低SDF-1诱导的迁移 。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T47D MWnDfZRwfG:6aXPpeJkh[XO|YYm= M4XJZVczKGi{cx?= NXLRPIJbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC5yMTFOwG0v M3;VTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNE[zPVQ1Lz5{MUS2N|k1PDxxYU6=
MDA468 M3:zT2N6fG:2b4jpZ4l1gSCjc4PhfS=> NYrzbnJRPzJiaILz M3v6U2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTR4ODDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC5yMjFOwG0v MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR4M{m0OEc,OjF2NkO5OFQ9N2F-
MCF7 NGXKemREgXSxdH;4bYNqfHliYYPzZZk> NXLueHlFPzJiaILz MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlA2KM7:TT6= NX[2SYNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OlM6PDRpPkKxOFY{QTR2PD;hQi=>
HCT116 NX3D[ppIS3m2b4TvfIlkcXS7IHHzd4F6 NF76c2U4OiCqcoO= Mk\aR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjB3IN88UU4> NFrJXHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS2N|k1PCd-MkG0OlM6PDR:L3G+
MDA468 MmXNR5l1d3SxeHnjbZR6KGG|c3H5 NHHDRmo1QCCqcoO= MkPuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCPDZ6IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjNyMjFOwG0v MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR4M{m0OEc,OjF2NkO5OFQ9N2F-
MDA468 NXLKWGxyS3m2b4TvfIlkcXS7IHHzd4F6 M1v6d|I1KGi{cx?= Mk\jR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCPDZ6IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjZyMTFOwG0v MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR4M{m0OEc,OjF2NkO5OFQ9N2F-
MRC5 NEfKU4REgXSxdH;4bYNqfHliYYPzZZk> MliyO|IhcHK| MnvXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBIUTVyIE2gNE44OSEQvF2u NH\ZNGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS2N|k1PCd-MkG0OlM6PDR:L3G+
MCF7 MUfGeY5kfGmxbjDhd5NigQ>? MWixJJVO NIPHcIlO\XSjYn;sbYMhe3SjYnnsbZR6KG:oIITo[UBkd22yb4Xu[EBqdiCqdX3hckBOS0Z5IHPlcIx{KGG2IEGgeW0> NVfsOZkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OlM6PDRpPkKxOFY{QTR2PD;hQi=>
MRC5 M2[0dWZ2dmO2aX;uJIF{e2G7 NXnWNncyOSC3TR?= NHS2RZJO\XSjYn;sbYMhe3SjYnnsbZR6KG:oIITo[UBkd22yb4Xu[EBqdiCqdX3hckBOWkN3IHPlcIx{KGG2IEGgeW0> NWW3RWNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OlM6PDRpPkKxOFY{QTR2PD;hQi=>
K562 NV;XWFNpS3m2b4TvfIlkcXS7IHHzd4F6 NXGwWYQ{QTZiaILz NWDoR4ZWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA6PiCqcoOgZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCLQ{WwJF0hOC5yMEe1JO69VS5? M1;tO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFIyLz5{MUixNlQzOTxxYU6=
DU145 NXzoUHRnS3m2b4TvfIlkcXS7IHHzd4F6 NEHkPZc6PiCqcoO= MlHmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgPVYhcHK|IHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3MDC9JFAvODd3IN88UU4> M2SyZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFIyLz5{MUixNlQzOTxxYU6=
HeLa NVW3R4xnSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MnfrO|IhcHK| NVSxNVFtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFEzKM7:TT6= MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
LNCAP NVzsTYlCSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1PPW|czKGi{cx?= MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFHSJJBwe2m2aY\lJIh2dWGwIFzOR2FRKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFI2KM7:TT6= NH\t[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVg4Oyd-MkS0O|E5PzN:L3G+
PANC1 M171WGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MU[3NkBpenN? NHm1dHFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDBUmMyKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFM6KM7:TT6= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUi3N{c,OjR2N{G4O|M9N2F-
MCF7 MnfsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlyyO|IhcHK| M1rBTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSXIheG:|aYTpeoUhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlA2KM7:TT6= MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
MCF7 MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M17xblczKGi{cx?= Mnj4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEWg{txONg>? NXHHeZZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|E5PzNpPkK0OFcyQDd|PD;hQi=>
MDA-MB-231 NGW3XZNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUC3NkBpenN? MkXZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDFVkBv\WejdHn2[UBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEW3JO69VS5? NWO4S5ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|E5PzNpPkK0OFcyQDd|PD;hQi=>
A2780 NFnlZYdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFH0cYc4OiCqcoO= NF;MWWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFYzKM7:TT6= MlH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
HCT116 M{W0RWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4X4O|czKGi{cx?= M1;zU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFch|ryPLh?= MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
DU145 M3vCfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{\ZXFczKGi{cx?= M1rvNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRXIhdmWpYYTpeoUhcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBIUTVyIE2gNE4xPzVizszNMi=> MkjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4O|MoRjJ2NEexPFc{RC:jPh?=
A2780 MXLGeY5kfGmxbjDhd5NigQ>? MkK5NE4zPSC3TR?= MnfPNlQhcHK| MYDS[YR2[3Srb36gbY4hS0SFMkXDJIxmfmWuIHnuJIh2dWGwIFGyO|gxKGOnbHzzJIF1KDBwMkWgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NXu0SFR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|E5PzNpPkK0OFcyQDd|PD;hQi=>
A2780 NH7YUFNCeG:ydH;zbZMh[XO|YYm= NFP0e5AxNjJ3IIXN MnG4NlQhcHK| MofrTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCDMke4NEBk\WyuczDhd5Nme3OnZDDhd{Bk[XOyYYPlMVMwPyCjY4TpeoF1cW:wIHH0JFAvOjVidV2gZYZ1\XJiMkSgbJJ{KGK7IIXzbY5oKEGybz3PUmUhcG:vb3flcoVwfXNiY3HzdIF{\S1|L{egb4l1 MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUi3N{c,OjR2N{G4O|M9N2F-
A2780 NHiyZY1HfW6ldHnvckBie3OjeR?= NGTPWWUxNjJ3IIXN NVLYNI5NOjRiaILz MUjS[YR2[3Srb36gbY4hVWOuMTDs[ZZmdCCrbjDoeY1idiCDMke4NEBk\WyuczDheEAxNjJ3IIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NFrKVZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVg4Oyd-MkS0O|E5PzN:L3G+
Assay
Methods Test Index PMID
Western blot pAbl / Abl / PCrk-L / Crk-L / Cleaved caspase3 / Cleaved PARP / pHistone H2A.X 26008977
Immunofluorescence p-ATF / COX IV 27764820
Growth inhibition assay GI50 Cell viability 29108241 27764820
体内研究 Rigosertib按250 mg/kg剂量作用于携带Bel-7402,MCF-7,和MIA-PaCa细胞的鼠移植瘤模型,明显抑制肿瘤生长。[1]Rigosertib按200 mg/kg剂量作用于携带BT20细胞的鼠移植瘤模型,也抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
  • 体外测定PLK1的酶实验:

    10 ng 重组PLK1和不同浓度Rigosertib在15 µL反应混合物(50 mM HEPES,10 mM MgCl2,1 mM EDTA,2 mM二硫苏糖醇,0.01% NP-40,pH 为7.5)中在室温下反应30分钟。激酶反应在20 µL反应混合物[15 µL 酶 + 抑制剂, 2 µL 1 mM ATP, 2 µL γ32P ATP (40 μci), 和1 µL 重组Cdc25C (100 ng)或酪蛋白 (1 μg) 底物]在30oC下进行20分钟。在20 µL 2× Laemmli buffer中沸腾2分钟终止反应。通过18% SDS-PAGE分离磷酸化的底物。烘干凝胶柱,用X-射线处理3-10分钟。

细胞实验:[2]
  • Cell lines: 多种肿瘤细胞系,包括 BT20,MCF-7,DU145,PC3,U87,A549,H187,RF1,HCT15,HeLa,和Raji细胞
  • Concentrations: 1 nM-10 µM, 溶于DMSO,作为储存液
  • Incubation Time: 96小时
  • Method: 细胞生长在含10%FBS和1 unit/mL青霉素-链霉亲和素溶液的DMEM或RPMI培养基中。肿瘤细胞按每孔1×105个细胞接种在6孔板上,24小时后,加入不同浓度Rigosertib。处理96小时后,测定每孔细胞数。通过台酚蓝染色测定全部存活细胞数。
动物实验:[1]
  • Animal Models: 携带Bel-7402,MCF-7,和MIA-PaCa细胞的雌性无胸腺NCR-nu/nu鼠
  • Dosages: 250 mg/kg
  • Administration: 腹腔注射

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water

95mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 473.47
化学式

C21H24NNaO8S

CAS号 1225497-78-8
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04177498 Recruiting Drug: Rigosertib Sodium|Other: Quality-of-Life Assessment Recessive Dystrophic Epidermolysis Bullosa Thomas Jefferson University|Onconova Therapeutics Inc. August 24 2021 Early Phase 1
NCT02075034 Withdrawn Drug: rigosertib Myelodysplastic Syndrome Onconova Therapeutics Inc. May 2014 Phase 1
NCT02030639 Completed Drug: rigosertib Healthy Onconova Therapeutics Inc. January 2014 Phase 1
NCT01928537 Completed Drug: rigosertib sodium Myelodysplastic Syndromes|Refractory Anemia With Excess Blasts|Chronic Myelomonocytic Leukemia|Cytopenia Onconova Therapeutics Inc. August 2013 Phase 3
NCT01807546 Completed Drug: rigosertib Head and Neck Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|Lung Squamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Esophageal Squamous Cell Carcinoma|Skin Squamous Cell Carcinoma|Penile Squamous Cell Carcinoma Onconova Therapeutics Inc. March 2013 Phase 2
NCT01168011 Completed Drug: rigosertib Solid Tumor Onconova Therapeutics Inc. July 2010 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy Rigosertib (ON-01910) | Rigosertib (ON-01910) supplier | purchase Rigosertib (ON-01910) | Rigosertib (ON-01910) cost | Rigosertib (ON-01910) manufacturer | order Rigosertib (ON-01910) | Rigosertib (ON-01910) distributor